#ASCO22 – Phase II RCT: Ramucirumab and pembrolizumab vs. standard of care in advanced non–small-cell lung cancer previously treated with immunotherapy.
6 Jun, 2022 | 11:14h | UTCCommentary: New drug combination lengthened survival for some with lung cancer – SWOG Cancer Research Network
Commentary on Twitter
? #ASCO22 simultaneous pub: Lung-MAP study finds ramucirumab ➕ pembro improved OS in pts w #NSCLC previously treated w/ immune ✔️point inhibitors & chemo. https://t.co/M0zL95ddxD @ReckampK @DrRoyHerbstYale #lcsm
— Journal of Clinical Oncology (@JCO_ASCO) June 3, 2022